Rubicon Research Limited Q2 Profit Rises 68% to ₹90.4 Crore

Rubicon Research Limited reported Q2 FY27 net profit of ₹90.4 crore, up 67.7% year-on-year, on revenue from operations of ₹576.4 crore, which increased 39.9%. The company also raised its FY27 operating EBITDA margin guidance to more than 24% from more than 23%, while regulatory inspections and new-facility execution remained relevant factors.

What did Rubicon Research report for Q2 FY27?

Rubicon Research reported consolidated revenue from operations of ₹576.4 crore for the quarter ended September 30, 2026, compared with ₹412.0 crore in Q2 FY26. The 39.9% year-on-year increase was accompanied by a 67.7% rise in net profit to ₹90.4 crore.

Operating EBITDA rose 52.8% year-on-year to ₹144.1 crore. Operating EBITDA margin stood at 25.0%, while EBITDA including other income was ₹146.4 crore and carried a 25.4% margin, according to the investor presentation. The difference between operating EBITDA and EBITDA including other income is relevant when comparing the quarterly margin with the company’s operating-margin guidance.

For the first half of FY27, revenue reached ₹1,110.7 crore, up 45.3% year-on-year. Net profit for the six-month period was ₹175.2 crore, a year-on-year increase of 80.3%. These reported figures show that profit growth exceeded revenue growth during both the quarter and the first half.

Why did Rubicon Research raise its FY27 margin guidance?

Rubicon Research raised FY27 operating EBITDA margin guidance by 1 percentage point, from more than 23% to more than 24%. The revised guidance followed a Q2 operating EBITDA margin of 25.0%, above the new full-year threshold.

Management also highlighted improved research and development productivity. Senior Vice President of Corporate Development and Strategy Sagar Oak said R&D productivity improved to 5.9 times in the FY23-FY26 cycle from 3.3 times in the FY21-FY24 cycle. For the current FY24-FY27 cycle, the measure was 5.8 times based on annualised first-half revenue.

The company had spent ₹313 crore of its planned ₹500 crore R&D expenditure for FY27, with the remaining spending expected over the next three quarters. R&D investment is central to the company’s pipeline and commercialisation plans, but the disclosed spending also means a substantial part of the annual programme was still pending after the first half.

How did acquisitions and product approvals support quarterly growth?

The earnings-call summary said quarterly revenue included ₹19.4 crore from an acquisition, meaning the reported growth rate includes an inorganic contribution. Rubicon Research had acquired Arinna Lifesciences Limited, an India-focused CNS formulations company with 60 brands and about 160 sales representatives, in April 2026. Arinna’s financials were consolidated from Q1 FY27.

Chief Executive Officer Parag Sancheti said three approvals were received during Q2 and cited an 84% commercialisation rate. These metrics point to continued conversion of regulatory approvals into marketed products, although the supplied materials do not provide revenue by product or by approval.

Management also referred to changes in India’s licensing process for controlled and other products. Under the revised process described on the call, FDA approval is required before an export-licence application can be made. This adds a regulatory sequencing requirement for affected products.

What regulatory and operational issues remain unresolved?

Recent plant inspections remained unresolved at the time of the earnings call. The provided materials refer to US FDA inspection-related disclosures for Rubicon Research’s manufacturing facility in Satara, Maharashtra, but do not state that the observations had been closed.

The call summary also identified pre-revenue facilities as an outlook consideration. New facilities can support capacity and future product launches, but they can affect reported profitability before they begin contributing revenue. The available disclosures do not quantify the cost or revenue impact of these facilities in Q2.

These factors matter because the company’s upgraded margin guidance is based on current operating performance while some regulatory and facility-related execution items are still open. The materials do not provide a timetable for resolving inspection observations or for bringing the facilities to revenue-generating status.

What does the Q2 performance mean for investors and operations?

The quarter shows revenue growth of nearly 40%, operating EBITDA growth of more than 52%, and net-profit growth of nearly 68%. The higher rate of profit growth and the 25.0% operating EBITDA margin provide the factual basis for management’s increase in full-year margin guidance.

For investors, acquisition-led revenue should be viewed alongside underlying operating trends. The company reported 5% sequential growth in US-dollar terms and disclosed a ₹19.4 crore acquisition contribution, but it did not provide a separate organic revenue-growth figure in the supplied materials.

For operations, product approvals, commercialisation and R&D productivity support the reported performance. At the same time, the revised export-licensing process, unresolved inspections and pre-revenue facilities remain disclosed execution issues. No share-price movement or market valuation data were included in the provided information.

Conclusion

Rubicon Research delivered a strong Q2 FY27 on reported measures, with ₹576.4 crore of revenue, ₹144.1 crore of operating EBITDA and ₹90.4 crore of net profit. The company’s decision to raise operating EBITDA margin guidance to more than 24% reflects quarterly profitability, R&D productivity and the contribution from its consolidated acquisition.

The next disclosures to watch are progress on the remaining ₹187 crore of planned FY27 R&D expenditure, commercialisation following the three Q2 approvals, and updates on unresolved plant inspections and pre-revenue facilities. The company has not disclosed a closure timeline for these operational matters in the supplied materials.